医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Gyros Protein Technologies Establishes Dedicated Office in Japan

2016年09月23日 AM12:18
このエントリーをはてなブックマークに追加


 

UPPSALA, Sweden

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced it has established a dedicated office in Tokyo, Japan and has established Gyros Japan KK.

The dedicated Japan team provides sales, applications and service support in Japan for the Company’s Gyros’ immunoassay business. Gyros Japan KK replaces support previously provided under the distribution agreement in Japan with GE Healthcare for Gyros Protein Technologies’ nanoliter-scale immunoassay platform business (Gyrolab xP workstation, Gyrolab xPlore, related reagents, consumables and service).

GE Healthcare will continue providing support for sales, technical support and maintenance service until the end of December 2016. Gyros Japan KK will take over full responsibility for the region from January 2017, ensuring a smooth transition for customers.

Peter Luk, Vice President Asia-Pacific, Gyros Protein Technologies, said: “We are delighted to announce the opening of the Japan office, and would like to thank GE Healthcare for their continued support during this transition period. This marks an important development for Gyros Protein Technologies and demonstrates the company’s commitment to the Asia-Pacific region, which has seen significant growth in the biotherapeutic discovery, development and manufacturing markets in recent years.”

ENDS

Notes to editors

Peter Luk, Vice President Asia-Pacific, Gyros Protein Technologies

For a high resolution image please contact Zyme Communications

About Gyros Protein Technologies (For more information please click here)

Gyros Protein Technologies, enables peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. Our low to mid-scale peptide synthesizer platforms are the Tribute®, Prelude® X, Symphony® X, and Sonata®. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab™xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide synthesis and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160922005908/en/

CONTACT

For Gyros
Katie Odgaard
Zyme Communications
Tel:
+44(0)7787 502 947
Email: Katie.odgaard@zymecommunications.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究